Structure Therapeutics (NASDAQ:GPCR) Issues Earnings Results, Misses Estimates By $0.33 EPS

Structure Therapeutics (NASDAQ:GPCR) announced its quarterly earnings data on Monday. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.33), FiscalAI reports.

Structure Therapeutics Trading Up 5.2%

GPCR stock opened at $21.41 on Tuesday. The company has a 50 day simple moving average of $30.00 and a 200 day simple moving average of $47.45. Structure Therapeutics has a 1 year low of $18.70 and a 1 year high of $94.90.

Analyst Ratings Changes

GPCR has been the topic of several recent analyst reports. Wall Street Zen lowered Structure Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, October 3rd. Weiss Ratings raised Structure Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, November 4th. Citizens Jmp restated a “market outperform” rating and set a $110.00 price objective on shares of Structure Therapeutics in a research report on Wednesday, September 9th. Citigroup reaffirmed a “market outperform” rating on shares of Structure Therapeutics in a research note on Friday, August 7th. Finally, Canaccord Genuity Group set a $111.00 price objective on Structure Therapeutics in a research note on Friday, August 7th. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Structure Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $110.91.

Structure Therapeutics Company Profile

Structure Therapeutics is a clinical-stage biopharmaceutical company developing medicines for metabolic and other chronic diseases. Its research approach uses structural biology and computational methods to identify and design small-molecule drug candidates.

The company’s pipeline includes aleniglipron, an oral small-molecule GLP-1 receptor agonist being developed for obesity and related metabolic conditions. Structure Therapeutics is also advancing other drug candidates targeting biological pathways associated with metabolic disease.

Founded in 2016, the company has operations in the United States and China.